Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Multiple Sclerosis (MS) subjects who have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 and a baseline Expanded Disability Status Scale (EDSS) between 0.0 and 5.0, inclusive, who meet either of the following 2 criteria:~  * Have experienced at least 1 relapse within the 12 months prior to randomization, with a cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with MS , OR~ * Show evidence of gadolinium-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to randomization.~Key Exclusion Criteria:~* Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS~* History of malignancy~* History of severe allergic or anaphylactic reactions or known drug hypersensitivity~* History of abnormal laboratory results based on investigator judgment~* History of human immunodeficiency virus (HIV) or other immunodeficient conditions~* History of drug or alcohol abuse within the 2 years prior to randomization~* An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization~* Positive screening for active infection with Hepatitis B virus or Hepatitis C virus~* Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before Screening~* Exposure to varicella zoster virus within 21 days before Screening.~* Abnormal blood tests at Screening: Hemoglobin ≤9.0 g/dL, Platelets ≤100 × 10\^9/L, Lymphocytes ≤1.0 × 10\^9/L, Neutrophils ≤1.5 × 10\^9/L, alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), or gamma-glutamyl-transferase \>2 times the upper limit of normal (ULN) and serum creatinine \>ULN.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
- 150 mg DAC HYP (Type: EXPERIMENTAL): Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
- 300 mg DAC HYP (Type: EXPERIMENTAL): Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).